Nautilus Biotechnology Inc.

San Carlos, California

Classification

Public

About

About

Nautilus Biotechnology, Inc. is a biotechnology company dedicated to revolutionizing the field of life sciences through innovative and advanced technologies. The company is focused on developing transformative tools and solutions that enable researchers, scientists, and clinicians to gain deeper insights into the complexities of biological systems. By leveraging state-of-the-art techniques, Nautilus aims to accelerate scientific discovery, enhance diagnostics, and drive breakthroughs in various areas of biology and medicine. Product/Service Line Breakdown: 1. Omics Platform: Nautilus Biotechnology's flagship product is its highly sophisticated omics platform, which integrates multiple "-omics" technologies such as genomics, proteomics, and transcriptomics. This comprehensive platform enables simultaneous analysis of various biological molecules at an unprecedented scale and resolution. Researchers and scientists can utilize this platform to unravel intricate biological networks, identify biomarkers, and uncover novel therapeutic targets. The omics platform provides a holistic view of cellular and molecular interactions, driving advancements in fields like personalized medicine, drug development, and biomarker discovery. 2. High-Throughput Sequencing: The company offers cutting-edge high-throughput sequencing technologies that empower researchers to rapidly sequence and analyze large volumes of genetic material. This capability is crucial for understanding genetic variations, identifying disease-associated mutations, and studying the dynamic behavior of genes. Nautilus' high-throughput sequencing solutions contribute to accelerating genomics research, paving the way for breakthroughs in genetics, evolutionary biology, and precision medicine. 3. Data Analysis and Interpretation: Nautilus Biotechnology provides advanced bioinformatics and data analysis tools that help researchers derive meaningful insights from complex biological datasets. The company's expertise lies in developing algorithms and software to process and interpret massive amounts of omics data. By offering user-friendly interfaces and powerful analytical capabilities, Nautilus enables scientists to extract valuable information from intricate biological datasets, ultimately enhancing research productivity and driving data-driven decision-making. 4. Collaborative Research Services: In addition to its technology offerings, Nautilus Biotechnology collaborates with research institutions, academic partners, and pharmaceutical companies to jointly address complex scientific challenges. The company's team of skilled experts provides consulting, experimental design, and research support to help clients optimize their studies and leverage Nautilus' technologies effectively. Collaborative research initiatives foster cross-disciplinary innovation and facilitate the translation of scientific discoveries into tangible applications. 5. Industry Partnerships: Nautilus Biotechnology actively seeks partnerships and collaborations with industry leaders, academic institutions, and healthcare organizations. These collaborations aim to combine Nautilus' technological expertise with diverse perspectives and resources, accelerating the development of novel solutions for healthcare, agriculture, environmental sciences, and more.

Financials

Revenue & Profit

Revenue

Valuation

Valuation

Ratios

Revenue / EBITDA
$123 MM
Valuation / Revenue
$123 MM
Valuation / Employees
$123 MM
EBITDA / Revenue
$123 MM
1-Year CAGR (Revenue)
03
3-Year CAGR (Revenue)
11
1-Year CAGR (Employees)
19
3-Year CAGR (Employees)
96

People

Employee Figures

Employees

Key Executives

NameTitleSocialsEmailPhone
John DoeEmployee
--
Jane DoeEmployee
John DoeEmployee
John DoeEmployee

401K

Total Active Participants
1234
No. Participants with Account Balances
56789
Total Liabilities Start of Year
1234
Total Assets Start of Year
56789

Deals

M&A2024-03-15Completed

Seller

Founders Group

Investor Sponsors

NorthBridge PE

Deal Amount

$120M

Target Company Valuation

$1.20 MM

Techniques

Acquisition of Assets, Taken Private

Stake Tags

100%

Is PE deal

Yes

Is deal PE backed

Yes

Total Acquired

100%

Secondary Transaction2023-09-01Canceled

Target

BrightHealth Technologies

Seller

Early Investors Consortium

Investor Sponsors

--

Deal Amount

Undisclosed

Target Company Valuation

NaN

Techniques

Secondary Sale, Management Buy-out (MBO)

Stake Tags

Majority

Is PE deal

No

Is deal PE backed

Yes

Total Acquired

65%

Funding

Keywords

Keywords

Classified

Private